Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK4382276A mRNA influenza vaccine in healthy adults
NCT05446740Phase 1Completed
- Sponsor
- GSK
- Start
- Aug 2022
- Primary completion
- Mar 2024
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 3
01
Overview
Phase 1, randomised trial of GSK4382276A in influenza, sponsored by GSK. Primary endpoints: Number of Participants Reporting Any Solicited Administration Site Events, Number of Participants Reporting Any Solicited Systemic Events and 2 more. Started Aug 2022; status: completed.
02
Drugs
GSK4382276A
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05446740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05446740.